John Strickler

Positions:

Associate Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2005

University of Chicago

Residency, Medicine

University of Washington

Fellowship in Hematology-Oncology, Medicine

Duke University School of Medicine

Grants:

CGX1321-101

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

CO40939

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Nektar

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

AbbVie M14-064

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

AbbVie M16-438

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer

Authors
Camidge, DR; Barlesi, F; Goldman, J; Morgensztern, D; Heist, R; Vokes, E; Spira, A; Angevin, E; Su, W; Hong, D; Strickler, J; Motwani, M; Sun, Z; Parikh, A; Komarnitsky, P; Wu, J; Kelly, K
MLA Citation
Camidge, D. R., et al. “MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology, vol. 14, no. 10, Elsevier BV, 2019, pp. S305–06. Crossref, doi:10.1016/j.jtho.2019.08.612.
URI
https://scholars.duke.edu/individual/pub1417837
Source
crossref
Published In
Journal of Thoracic Oncology
Volume
14
Published Date
Start Page
S305
End Page
S306
DOI
10.1016/j.jtho.2019.08.612

OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC

Authors
Govindan, R; Fakih, M; Price, T; Falchook, G; Desai, J; Kuo, J; Strickler, J; Krauss, J; Li, B; Denlinger, C; Durm, G; Ngang, J; Henary, H; Ngarmchamnanrith, G; Rasmussen, E; Morrow, P; Hong, D
MLA Citation
Govindan, R., et al. “OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC.” Journal of Thoracic Oncology, vol. 14, no. 10, Elsevier BV, 2019, pp. S208–S208. Crossref, doi:10.1016/j.jtho.2019.08.412.
URI
https://scholars.duke.edu/individual/pub1417838
Source
crossref
Published In
Journal of Thoracic Oncology
Volume
14
Published Date
Start Page
S208
End Page
S208
DOI
10.1016/j.jtho.2019.08.412

Abstract 1675: Analytical validation of MSI High detection with GuardantOMNI

Authors
Zhao, J; Artyomenko, A; Artieri, C; Latham, J; Fairclough, SR; Barbacioru, C; Helman, E; Strickler, J; Chudova, D; Lanman, R; Talasaz, A
MLA Citation
Zhao, Jing, et al. “Abstract 1675: Analytical validation of MSI High detection with GuardantOMNI.” Bioinformatics, Convergence Science, and Systems Biology, American Association for Cancer Research, 2019. Crossref, doi:10.1158/1538-7445.am2019-1675.
URI
https://scholars.duke.edu/individual/pub1416462
Source
crossref
Published In
Bioinformatics, Convergence Science, and Systems Biology
Published Date
DOI
10.1158/1538-7445.am2019-1675

Abstract LB-235: COLOMATE: Colorectal cancer and liquid biopsy screening protocol for molecularly assigned therapy

Authors
Ciombor, KK; Ou, F-S; Dodge, A; Zemla, T; Wu, C; Ng, K; Pedersen, K; Kato, S; Kasi, PM; Ahn, D; Nagy, R; Lanman, R; Kopetz, S; Strickler, JH; Bekaii-Saab, T
MLA Citation
Ciombor, Kristen K., et al. “Abstract LB-235: COLOMATE: Colorectal cancer and liquid biopsy screening protocol for molecularly assigned therapy.” Clinical Research (Excluding Clinical Trials), American Association for Cancer Research, 2019. Crossref, doi:10.1158/1538-7445.am2019-lb-235.
URI
https://scholars.duke.edu/individual/pub1416463
Source
crossref
Published In
Clinical Research (Excluding Clinical Trials)
Published Date
DOI
10.1158/1538-7445.am2019-lb-235

Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.

Authors
Isaacs, J; Nixon, AB; Bolch, E; Quinn, K; Banks, K; Hanks, BA; Strickler, JH
MLA Citation
Isaacs, James, et al. “Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers..” Journal of Clinical Oncology, vol. 37, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2019, pp. 3552–3552. Crossref, doi:10.1200/jco.2019.37.15_suppl.3552.
URI
https://scholars.duke.edu/individual/pub1414970
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date
Start Page
3552
End Page
3552
DOI
10.1200/jco.2019.37.15_suppl.3552